Figure 2.

UM cells were sensitive to AURKB inhibitors. Four aurora kinase inhibitors, including AURKB-specific inhibitor hesperadin (A), dual-target inhibitor targeting AURKA/B TAK-901 (B), pan-aurora kinase inhibitor danusertib (C), and AURKA-specific inhibitor Aurora A inhibitor I (D) were examined for their antitumor efficacy on four UM cell lines (92.1, MEL290, OMM2.3, and XMP46) and one cutaneous melanoma cell line A375. The half maximal inhibitory concentration (IC50) values were calculated using GraphPad Software 8.0.1.